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Prognostic Impact of Histologic Subtype in Non-Small 
Cell Lung Cancer Patients Treated with Gamma Knife 
Radiosurgery: Retrospective Analysis of 104 Patients
ABSTRACT
and location. The brain has been reported to be the most com-
mon region for metastasis in patients with lung cancer, with a 
rate of 20-50%. Treatment options include whole-brain radia-
tion therapy (WBRT), stereotactic radiosurgery (SRS), surgery, 
or a combination treatment (4). The effect of application of 
SRS alone or in combination with WBRT on brain metastasis 
█    INTRODUCTION
Brain metastases (BM) have been reported in 40% of pa-tients with cancer (15). The factors that determine treat-ment options in patients with brain metastasis are age, 
Karnofsky Performance Scale (KPS), primary tumor histopa-
thology, radiosensitivity, number of intracranial metastasis, 
AIm: In this study, factors affecting survival, local failure, distant brain failure, whole brain failure and whole-brain radiation therapy 
(WBRT) free survival according to histological subtypes were investigated in patients with brain metastases from non-small cell lung 
cancer (NSCLC).    
mATERIAl and mEThODS: Patients with positive pathology reports for adenocarcinoma (ACA) and squamous cell carcinoma 
(SCC) were included in the study. Seventy-eight ACA and 26 SCC patients were included in the study. Patients with previous history 
of cerebral metastasis surgery and WBRT were excluded from the study.    
RESUlTS: The median survival was calculated as 12.6 months for patients with ACA and 5.9 months for patients with SCC. 
One-year distant brain failure was calculated as 65.1% in ACA patients and 39.6% in SCC patients. One-year whole brain failure 
was calculated as 58.1% in ACA patients and 39.6% in SCC patients. The one-year freedom from WBRT rate was calculated as 
72.8% in ACA patients and 56.3% in SCC patients. SCC histology was considered as a significant factor in deterioration of overall 
survival in multivariate analysis. SCC histology, the increase in the number of metastases and RPA class were factors that caused 
an increase in distant brain failure. Also, SCC histology, the increase in the number of metastases and RPA class were factors that 
caused an increase in whole brain failure.   
CONClUSION: SCC histology may be an important prognostic factor for overall survival. Also, due to high distant brain failure rate 
in SCC histology, WBRT can be added to treatment early.        
KEywORDS: Cranial metastases, Gamma knife radiosurgery, Non-small cell lung cancer
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has been investigated in several studies. In a study published 
by Aoyama et al., it was reported that although addition of 
WBRT to the treatment regime of patients who had undergone 
SRS provided a reduction in relapses, it was not effective in 
lengthening average survival times (2). Adding WBRT to the 
treatment regime of patients with one to three brain metas-
tases treated with SRS or surgery decreased intracranial re-
currence and neurological mortality. However, improvement in 
functional independence and mean survival time has not been 
determined (10). The most important problem with WBRT is 
that it is associated with worsening neurocognitive functions. 
Chang et al. found that the risk of decrease in learning and 
memory functions in the first four months after treatment is 
higher in patients treated with SRS and WBRT than in patients 
treated only with SRS (7). In a study published by Tsao et al., 
it was reported that control of local and distant brain metas-
tases in patients treated with only SRS was less successful 
compared to patients treated with SRS and WBRT (19). 
In recent studies, the histological subtype of the primary tumor 
has been emphasized to be important in the natural course 
of brain metastases. Histological subtypes of lung cancer 
are known to behave differently in the natural course of the 
disease. Small cell lung cancer (SCLC) has a high rate of brain 
metastasis and prophylactic cranial irradiation is the standard 
treatment in these patients (3,17). In addition, survival of 
adenocarcinoma (ACA), a histological subtype of non-small 
cell lung cancer (NSCLC), is known to be better compared 
to squamous cell carcinoma (SCC) (6). Studies on the effects 
of different histological subtypes of NSCLC on the biological 
behavior of the brain metastases have increased recently.
In this study, we report retrospective examination of ACA 
and SCC patients who were treated with Gamma Knife 
Radiosurgery (GKRS) by a similar protocol in a single center 
and who did not receive therapeutic WBRT for diagnosed 
brain metastases. Factors affecting survival, local failure, 
distant brain failure, whole brain failure, and duration of life 
without WBRT were investigated.
█    mATERIAl and mEThODS
Study Design
The study was approved by the institutional review board of 
Baskent University before collection of patient information, 
and was conducted according to the principles of the 
Declaration of Helsinki and the rules of Good Clinical Practice 
(Project no: KA14/353). The medical records of patients 
treated with GKRS for brain metastases due to lung cancer 
in the Neurosurgery Department of Baskent University, Adana 
Training and Research Hospital between June 2011 and 
December 2014 were reviewed retrospectively. Patients with 
positive pathology reports for ACA and SCC were included in 
the study. Patients with previous history of cerebral metastasis 
surgery and WBRT were excluded from the study. Patient data 
were obtained from the electronic medical records system. 
Tumor volume and dosimetric data were obtained from the 
Gamma Plan treatment planning system (Gamma plan 10.0) 
archives.
Data Collection
Age, gender, histopathology, survival, control of primary dis-
ease, extracranial metastatic disease, Recursive Partitioning 
Analysis (RPA) class, time to cranial metastases after diag-
nosis of lung carcinoma, number of metastases, GKRS dose, 
local-distant and whole brain control, WBRT after gamma 
knife, WBRT-free time, and neurological death were recorded 
for patient data. Survival was calculated from the date of ap-
plication of GKRS. Local, distant, and whole brain control pe-
riod was calculated as the time from the date of application 
of GKRS to the time of local, distant, and whole brain failure 
(i.e., the date of the last radiological imaging in the absence 
of local, distant, and whole brain failure). WBRT-free time was 
calculated as the time from the date of application of GKRS to 
the date of application of GKRS and was equal to survival in 
WBRT-untreated patients. Recursive partitioning analysis was 
identified according to the analysis report by Gaspar et al. (8). 
Radiosurgery Technique
Patients were treated on a Leksell Model 4C Unit (Elekta, 
Stockholm, Sweden). Before radiosurgery, the patients under-
went a high-resolution contrast-enhanced stereotactic mag-
netic resonance imaging (MRI) study of the brain. Treatment 
planning was performed using the Leksell GammaPlan Treat-
ment Planning System (Gamma plan 10.0). A median dose of 
20 Gray (Gy; range: 14-24 Gy) was generally prescribed to 
the 50% isodose line at the margin of each metastasis. Dose 
prescription was based on guidelines published by Shaw et al. 
(16). Patients were treated one to four weeks after the detec-
tion of brain metastasis. A total of 200 tumors in 104 patients 
and a median of one lesion (range: 1-6) per patient were treat-
ed. Median tumor volume was 3.72 cm3 (range: 0.13-49.02 
cm3) in all patients, 2.72 cm3 (range: 0.13-40.21cm3) in ACA 
patients, and 8.82 cm3 (range: 0.23-49.02 cm3) in SCC pa-
tients. Total tumor volumes were greater than 30 cm3 in only 
four patients: two in SCC and two in ACA histology, respec-
tively.
Patient Follow-Up, Toxicity, Salvage Therapy
Patients were followed by serial MRIs, first at the eighth 
week after GKRS treatment and following ones with 3-month 
periods. The median follow-up time of the patients was 
8.8 months (mean: 10.7 months, range: 1.3-36.8 months). 
Local failure was defined by a combination of clinical and 
radiological signs of local treatment failure. Patients with 
suspected local treatment failure were generally followed 
initially with short interval imaging and were treated 
conservatively before determination of a treatment failure 
to rule out radiation necrosis. Local failures were treated 
with surgical excision, GKRS, or observation. In the case of 
local failure, we performed a cranial MRI for four consecutive 
weeks. If we defined progression of the tumor, we applied re-
GKRS. If we defined Grade 3 radionecrosis, surgical excision 
was performed. Distant brain progression was defined by the 
occurrence of new metastases that were not visible initially. 
Distant brain failures were generally treated with GKRS, and 
WBRT was generally reserved for four or more total brain 
metastases over time or for short-interval distant failures. 
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Whole brain failures were defined as failure to achieve local 
or distant control. Death due to intracranial progression was 
defined as “death due to specifically progressive neurological 
impairment with stable systemic disease” (14). Four patients 
developed Grade 3 radionecrosis and surgical excision was 
performed. GKRS was re-applied to 12 patients in whom local 
or distant failure was seen. 28.2% (22/76) of ACA patients and 
42.3% (11/26) of SCC patients underwent WBRT.
Statistical methods
Statistical analyses were performed based on patient 
stratification according to BM histology: ACA versus SCC. 
Frequency distributions were used to describe categorical 
variables, and mean, median, and ranges were used for 
quantitative variables. Demographic features were compared 
between the ACA and SCC cohorts using a Chi-square test. 
Overall survival, local tumor control, distant brain failure, 
whole brain failure, and WBRT-free survival of patients were 
calculated using Kaplan-Meier analysis. Survival times 
were calculated as the time between the first day of GKRS 
and the date of death/last visit for OS; the date of local or 
inbrain relapse, or the date of death/last visit for local tumor 
control; and distant brain failure time, and the time between 
the first day GKRS and the first day of WBRT for WBRT-free 
survival, respectively. Survival analysis was performed by the 
Kaplan-Meier method and the survival curves of subsets were 
compared with two-sided log-rank tests. Only the factors 
that exhibited statistical significance in univariate analysis 
were included in multivariate analysis that utilized Cox 
proportional hazards regression tests. Multivariate analyzes 
were performed for each survival end-point (i.e., overall 
survival, distant brain failure, whole brain failure, and WBRT-
free survival). All tests were two-tailed, and a p-value <0.05 
was considered significant.
█    RESUlTS
Patients Characteristics
78 ACA and 26 SCC patients were included in the study. 
87.5% of the patients were male and 12.5% were female. The 
median age of all patients was 60 years (range: 35-86 years); 
median age was 59.5 years (range: 35-86 years) for ACA 
patients and 65.5 years (range: 47-83 years) for SCC patients. 
Median time from diagnosis of lung cancer to diagnosis of 
brain metastasis was 2.5 months (range: 0.0-48.0 months) for 
all patients; it was one month (range: 0-48) for ACA patients 
and seven months (range: 0-34 months) for SCC patients. 
Extracranial metastatic disease was identified in 47.4% of 
ACA patients and 57.2% of SCC patients. 12.5% of patients 
were RPA Class 1, 73.1% were RPA Class 2, and 14.4% were 
RPA Class 3. Patient characteristics are summarized in Table I.
Univariate Analysis 
The Kaplan-Meier method was used to determine the effects 
of histology, age, gender, number of metastases, RPA class, 
volume, and extracranial metastases factors on overall 
survival, local tumor control, distant brain control, whole brain 
control, and WBRT-free survival. The number of metastases 
was classified as one or greater than one. Volume was 
classified as above and below 3.72 cm3, which is the average 
median volume of all patients. Univariate p-value is shown in 
Table II. 
Survival
The median overall survival for all patients was 8.5 months 
(95% CI: 3.8-13.2), whereas the one-year overall survival rate 
was 47.1%, and the two-year overall survival rate was 10.2%. 
According to the histopathology of the patients, the overall 
median survival was 12.6 months (95% CI: 8.8-16.4) for ACA 
patients and 5.9 months (95% CI: 4.4-7.4) for SCC patients 
(p=.024). One- and two-year overall survival rates were 
calculated as 53.8% and 12.8% in ACA patients and 26.9% 
and 0.0% in SCC patients, respectively. The Kaplan-Meier 
estimates of overall survival are shown in Figure 1. The median 
overall survival according to RPA classification was calculated 
as 14.3 months (95% CI: 11.8-16.8) for Class 1, 10.3 months 
(95% CI: 5.7-14.9) for Class 2, and 3.5 months (95% CI: 
2.5-4.5) for Class 3 (p<.0001). Kaplan-Meier estimates for 
overall survival stratified by RPA Class are found in Figure 
2. Overall median survival of patients without extracranial 
metastases was 14.1 months (95% CI: 12.9-15.3), whereas it 
was 4.9 months (95% CI: 4-5.7) in patients with extracranial 
metastases (p<.0001). Kaplan-Meier estimates for overall 
survival stratified by extracranial metastases are found in 
Figure 3. The effects of age, gender, volume, and the number 
of metastases on overall survival could not be demonstrated. 
95 of the 104 patients died during the analysis. The cause of 
death could not be determined in 16 patients. Death due to 
intracranial progression occurred in 23.1% (18/76) of ACA and 
30.8% (8/26) of SCC patients who died.
Figure 1: Kaplan-Meier plot of overall survival. (ACA, adenocarci-
noma; SCC, squamous cell carcinoma).
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(p=.006). One and two-year freedom from distant brain failure 
was calculated as 65.1% and 25.3% in ACA patients and 
39.6% and 19.8% in SCC patients, respectively. Kaplan-
Meier estimates for freedom from distant failure stratified 
by histology are found in Figure 4. RPA class (p=<.0001), 
presence of extracranial metastatic disease (p=.005) and 
the increase in the number of metastases (p=.001) all reduce 
distant control. The effects of age, gender, and volume on 
distant control could not be demonstrated statistically.
Median time of freedom from whole brain failure was12.4 
months (95% CI: 8.8-16) for all patients, whereas one- and 
two-year freedom from whole brain failure was calculated as 
53.2% and 8%, respectively. Median time of freedom from 
whole brain failure in ACA patients was 13.2 months (95% CI: 
11.3-15), whereas it was 5.7 months (95% CI: 4.3-7) in SCC 
patients (p=.013). One and two-year freedom from whole brain 
failure was calculated as 58.1% and 10.6% in ACA patients 
and 39.6% and 10.4% in SCC patients, respectively. Kaplan-
Meier estimates for freedom from whole-brain failure stratified 
local, Distant, and whole Brain Failure
Median time of freedom from local failure was 22.5 months 
(95% CI: 10.6-34.4) for all patients, whereas one- and two-year 
freedom from local failure was 87.0% and 41.4%, respectively. 
Median time of freedom from local failure in ACA patients was 
22.5 months, whereas it was 12.7 months (95% CI: 12.0-
13.3) in SCC patients (p=.116). One- and two-year freedom 
from local failure was calculated as 86.6% and 45.6% in ACA 
patients and 87.5% and 36.5% in SCC patients, respectively. 
The effects of age, gender, RPA class, extracranial metastatic 
disease, and number of metastases on local control could not 
be demonstrated statistically.
Median time of freedom from distant brain failure was 14.3 
months (95% CI: 10.6-18.0) for all patients, whereas one- and 
two-year freedom from distant brain failure was 58.5% and 
21.7%, respectively. Median time of freedom from distant brain 
failure in ACA patients was 15.7 months (95% CI: 12.7-18.7), 
whereas it was 5.7 months (95% CI: 4.3-7) in SCC patients 
Table I: Patient Characteristics
Characteristic Total(n=104)
ACA
(n=78)
SCC
(n=26) p-value
Age; years 
(range) 
60
(35-86)
59.5
(35-86)
65.5
(47-83) 0.17
Gender no. (%)
Male
Female 
91 (87.5)
13 (12.5)
67 (85.9)
11 (14.1)
24 (92.3)
2 (7.7)
0.93
RPA Class no.(%)
1
2
3
13 (12.5)
76 (73.1)
15 (14.4)
9 (11.5)
59 (75.6)
10 (12.8)
4 (15.4)
17 (65.4)
5 (19.2)
0.36
lesions treated, no. (%)
1
2
3
≥4
57 (54.8)
23 (22.1)
14 (13.5)
10 (9.6)
40 (51.3)
19 (24.4)
11 (14.1)
8 (10.2)
17 (65.4)
4 (15.4)
3 (11.5)
2 (7.7)
0.23
median tumor volume; (cm3) 3.72(0.13-49.02)
2.72
(0.13-40.21)
8.82
 (0.23-49.02) 0.01
median marginal dose, Gy (range) 20(14-24)
20
(14-24)
20
(14-24) 1.00
wBRT status (%)
Yes
No
33 (31.7)
71 (68.3)
22 (28.2)
56 (71.2)
11 (42.3)
15 (57.7) 0.86
local failures (%) 13 (12.5) 9 (11.5) 4 (15.4) 0.57
Distant failures (%) 39 (37.5) 26 (34.6) 13 (50) 0.08
whole brain failures (%) 46 (44.2) 31 (39.7) 15 (57.7) 0.03
Deaths due to intracranial progression (%) 26 (25) 18 (23.1) 8 (30.8) 0.18
Extracranial metastasis (%) 52 (50) 37 (47.4) 15 (57.2) 0.25
RPA: Recursive partitioning analysis, WBRT: Whole-brain radiation therapy.
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Table II: Univariate Analysis of Possible Predictive Factors for Overall Survival, Local, Distant, Whole Brain Control and Freedom from 
WBRT
OS lC DC wBC Freedom from wBRT
Factor p-value p-value p-value p-value p-value
Age (years)
≤60
>60
0.966 0.825 0.395 0.227 0.554
Gender
Male
Female
0.885 0.437 0.904 0.876 0.675
RPA
Class1
Class 2
Class 3
<0.0001 0.474 <0.0001 <0.0001 0.004
ECm
Yes
No <0.0001 0.611 0.005 0.005 0.24
histology
ACA
SCC 0.024 0.116 0.006 0.013 0.006
metastasis no
1
1<
0.574 0.592 0.001 0.003 0.001
Volume
<3.72 cm3
>3.72 cm3
0.515 0.523 0.704 0.719 0.853
OS: Overall survival, LC: Local control, DC: Distant control, WBC: Whole-brain control, WBRT: Whole-brain radiation therapy, RPA: Recursive 
partitioning analysis, ECM: Extracranial metastases, ACA: Adenocarcinoma; SCC: Squamous cell carcinoma.
Figure 2: Kaplan-Meier plot of overall survival. (RPA: Recursive 
partitioning analysis).
Figure 3: Kaplan-Meier plot of overall survival.
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were factors that caused an increase in whole brain failure. 
Although the effect of extracranial metastatic disease on 
distant control and whole brain control was shown in univariate 
analysis, no statistically significant effect was found in the 
multivariate analysis. SCC histology (p=.001) and number of 
metastases (p=.002) were factors that shortened WBRT-free 
time. RPA class (p=.052) tended to affect. The results of the 
multivariate analysis with associated p-values are shown in 
Table III.
by histology are found in Figure 5. RPA class  (p=<.0001), 
presence of extracranial metastatic disease (p=.005), and 
increase in the number of metastases (p=.003) all reduce 
whole brain control. The effects of age, gender, and volume 
on whole brain control could not be demonstrated statistically.
Time Delay to wBRT
Median time of freedom from WBRT was 17.8 months (95% CI: 
13.3-22.3) for all patients, whereas one- and two-year freedom 
from WBRT was calculated as 68.3% and 34.5%, respectively. 
Median time to application of WBRT in ACA patients was 18.6 
months (95% CI: 11.4-25.8), whereas it was 12.9 months 
(95% CI: 0.0-26.2) in SCC patients (p=.006). The one- and 
two-year freedom from WBRT rate was calculated as 72.8% 
and 39.9% in ACA patients and 56.3% and 21.1% in SCC 
patients, respectively (Figure 6). While RPA class (p=.004) and 
increase in the number of metastases (p=.001) reduced time 
of freedom from WBRT, the effects of age, gender, volume, 
and presence of extracranial metastatic disease on freedom 
from WBRT could not be demonstrated statistically.
multivariate Analysis
Multivariate analyses were performed using Cox proportional 
hazards regression testing. Factors that impacted overall 
survival, distant brain failure, whole brain failure, and WBRT-
free survival were evaluated. In multivariate analysis, SCC 
histology was considered as a significant factor on the 
deterioration of overall survival (p=.017). RPA class (p=.017) 
and extracranial metastasis (p=<.0001) were important factors 
that cause deterioration in overall survival. SCC histology 
(p=.001), increase in the number of metastases (p=.004), and 
RPA class (p=.004) were factors that caused an increase in 
distant brain failure. Also, SCC histology (p= .001), increase in 
the number of metastases (p=.009) and RPA class (p=<.0001) 
Figure 4: Kaplan-Meier plot of distant control. (ACA, adenocarci-
noma; SCC, squamous cell carcinoma).
Figure 5: Kaplan-Meier plot of whole-brain control. (ACA, 
adenocarcinoma; SCC, squamous cell carcinoma).
Figure 6: Kaplan-Meier plot of time to whole-brain radiation ther-
apy. (ACA, adenocarcinoma; SCC, squamous cell carcinoma).
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In the literature, few studies have shown the effect of NSCLC 
histological subtypes on survival. In RTOG 9508 study, NSCLC 
patients were grouped according to histological subtypes and 
survival of SCC after WBRT was found to be worse than in 
ACA (1). 
In a published series of 213 patients who did not receive 
therapeutic WBRT, Kuremsky et al. compared ACA, SCC, 
and SCLC cases (12). One-year survival of ACA patients was 
56% as opposed to 20% in SCC patients; in consideration 
of these differences in survival rates, the authors stated that 
histological subtype may represent a new variable between 
current prognostic indexes. They hypothesized there were 
two reasons for the difference between ACA and SCC survival 
rates. These reasons included later relative diagnosis of SCC 
and better success in systemic therapy of ACA compared to 
SCC in recent years were thought (12). However, Zairi et al. 
could not find a statistically significant difference between 
the results of ACA and SCC in a series of 89 cases (21). In 
our study, one-year survival of patients with ACA was 56.8%, 
while it was 26.9% in SCC patients. This result suggests that 
histology may be an important factor in survival. 
The risk of distant brain failure is known to increase in patients 
without primary tumor control. In our study, RPA class, large 
number of metastases, and extracranial metastases increased 
the risk of distant brain failure. Additionally, the distant brain 
failure rate in SCC patients was higher than the rate in ACA 
patients, and this increased the rate of WBRT application. 
Early addition of WBRT to treatment besides radio surgery 
should be considered in patients with SCC. Distant brain 
failure rate is low in ACA patients and WBRT can be used as 
a salvage regime.
This study had some limitations. As this is a retrospective 
study and was limited in the number of patients, the results 
█    DISCUSSION
Declines in quality of life and brain metastases that cause 
death due to intracranial progression have encouraged re-
searchers to find new therapeutic strategies. Several random-
ized trials have shown that local control and overall survival 
of patients treated with surgical excision and subsequent 
WBRT are better than outcomes for patients treated with 
WBRT alone (13,14,20). As a result, local control has been 
seen to be effective in overall survival and neurological status, 
so strategies to improve local control have been developed. 
Due to surgical complications and surgery causing delay in 
the treatment of primary disease, interest in radiosurgery has 
increased recently. Many studies also have shown that SRS 
combined with WBRT is superior in local control and overall 
survival compared to WBRT alone (1,11). 
Lung cancers usually cause brain metastases, and the litera-
ture has generally treated these as non-small cell and small 
cell cancer. Metastases of SCLC are known to have low local 
control rates and high rates of death due to intracranial pro-
gression. The mechanism for decreased local control in SCLC 
is unclear. However, populations of radioresistant cells, clono-
gens, and increased invasion into the brain parenchyma have 
been proposed as possible mechanisms. Thus, prophylactic 
WBRT became the standard for managing SCLC (5,9). KPS, 
age, number of metastases, and presence of extracranial me-
tastases were reported as the dominant factors affecting sur-
vival after the diagnosis of brain metastases of lung cancer 
(18). In our study, RPA class, extracranial metastatic disease 
and histology were identified as important factors for overall 
survival. According to our study, RPA Class 3 patients have a 
median survival of only 3.5 months and GKRS treatment for 
this group of patients should be questioned.
Table III: Multivariate Analysis of Possible Predictive Factors for Overall Survival, Local, Distant, Whole Brain Control and Freedom from 
WBRT
OS lC DC wBC Freedom from wBRT
Factor p-value p-value p-value p-value p-value
RPA
Class1
Class 2
Class 3
0.017 - 0.004 <0.0001 0.052
ECm
Yes 
No <0.0001 - 0.291 0.436 0.947
histology
ACA
SCC 0.017 - 0.001 0.001 0.001
metastasis no
1
1<
- - 0.004 0.009 0.002
OS: Overall survival, LC: Local control, DC: Distant control, WBC: Whole-brain control, WBRT: Whole-brain radiation therapy, RPA: Recursive 
partitioning analysis, ECM: Extracranial metastases, ACA: Adenocarcinoma, SCC: Squamous cell carcinoma.
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may have unexpected sources of bias. Although the number 
of patients diagnosed with SCC was statistically significant, 
the relatively small number of the patients decreased the 
statistical power of the study. In further studies, histological 
subtype should be considered an important prognostic factor.
█    CONClUSION
KPS, age, number of metastases, and presence of extracranial 
metastases are known factors that affect the overall survival 
in brain metastases of lung cancer. Our study suggests that 
SCC histology might also be an important factor for overall 
survival. In addition, WBRT may be added to treatment early 
in SCC due to the high rate of distant brain failure. We believe 
that specific studies that further investigate the impact of 
histological subtypes will contribute to the treatment protocol. 
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